HM9: Patient engagement in the regulatory lifecycle of medicines


The session was dedicated to considering how patient engagement is being considered as part of medicinal product development, approval, and post-approval phases. Involving patients in the regulatory decision-making process is advancing and progress has been made in evolving frameworks over the last few years. Four short presentations set the scene for discussion, with contributions from regulators, patient representatives and healthcare providers.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.


Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!